| Alteration of the myometrial plasma membrane cholesterol content with. Beta.-cyclodextrin modulates the binding affinity of the oxytocin receptor U Klein, G Gimpl, F Fahrenholz Biochemistry 34 (42), 13784-13793, 1995 | 668 | 1995 |
| Expression of the human oxytocin receptor in baculovirus-infected insect cells: high-affinity binding is induced by a cholesterol-cyclodextrin complex G Gimpl, U Klein, H Reilaender, F Fahrenholz Biochemistry 34 (42), 13794-13801, 1995 | 202 | 1995 |
| Next generation multifunctional angiotensin receptor blockers TW Kurtz, U Klein Hypertension Research 32 (10), 826-834, 2009 | 128 | 2009 |
| Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in … LG Hegde, C Yu, T Renner, H Thibodeaux, SR Armstrong, T Park, ... Journal of cardiovascular pharmacology 57 (4), 495-504, 2011 | 100 | 2011 |
| A novel interaction between adrenergic receptors and the α-subunit of eukaryotic initiation factor 2B U Klein, MT Ramirez, BK Kobilka, M von Zastrow Journal of Biological Chemistry 272 (31), 19099-19102, 1997 | 96 | 1997 |
| Heterologous inhibition of G protein-coupled receptor endocytosis mediated by receptor-specific trafficking of β-arrestins U Klein, C Müller, P Chu, M Birnbaumer, M von Zastrow Journal of Biological Chemistry 276 (20), 17442-17447, 2001 | 49 | 2001 |
| THRX-198321 is a bifunctional muscarinic receptor antagonist and β2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner T Steinfeld, AD Hughes, U Klein, JAM Smith, M Mammen Molecular pharmacology 79 (3), 389-399, 2011 | 43 | 2011 |
| Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo K McCluskie, U Klein, C Linnevers, Y Ji, A Yang, C Husfeld, GR Thomas Journal of Pharmacology and Experimental Therapeutics 319 (1), 468-476, 2006 | 43 | 2006 |
| Reconstitution of the myometrial oxytocin receptor into proteoliposomes: dependence of oxytocin binding on cholesterol U KLEIN, F FAHRENHOLZ European journal of biochemistry 220 (2), 559-567, 1994 | 42 | 1994 |
| Conversion of the myometrial oxytocin receptor from low to high affinity state by cholesterol. F Fahrenholz, U Klein, G Gimpl Advances in experimental medicine and biology 395, 311-319, 1995 | 38 | 1995 |
| A multivalent approach to the discovery of long-acting β2-adrenoceptor agonists for the treatment of asthma and COPD JR Jacobsen, SK Choi, J Combs, EJL Fournier, U Klein, JW Pfeiffer, ... Bioorganic & medicinal chemistry letters 22 (2), 1213-1218, 2012 | 33 | 2012 |
| Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1 H-indol-5-yl … SK Choi, D Green, A Ho, U Klein, D Marquess, R Taylor, SD Turner Journal of medicinal chemistry 51 (12), 3609-3616, 2008 | 24 | 2008 |
| Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD RM McKinnell, U Klein, MS Linsell, EJ Moran, MB Nodwell, JW Pfeiffer, ... Bioorganic & medicinal chemistry letters 24 (13), 2871-2876, 2014 | 18 | 2014 |
| A new tritiated oxytocin receptor radioligand—synthesis and application for localization of central oxytocin receptors U Klein, M Jurzak, R Gerstberger, F Fahrenholz Peptides 16 (5), 851-857, 1995 | 12 | 1995 |
| Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Neprilysin Inhibitor (ARNI) RM McKinnell, P Fatheree, SK Choi, R Gendron, K Jendza, B Olson Blair, ... ACS medicinal chemistry letters 10 (1), 86-91, 2018 | 11 | 2018 |
| Multivalent design of long-acting β2-adrenoceptor agonists incorporating biarylamines JR Jacobsen, JB Aggen, TJ Church, U Klein, JW Pfeiffer, TM Pulido-Rios, ... Bioorganic & medicinal chemistry letters 24 (12), 2625-2630, 2014 | 11 | 2014 |
| Enhanced selectivity of oxytocin antagonists containing sarcosine in position 7 I Pavo, J Slaninova, F Fahrenholz, U Klein Journal of medicinal chemistry 37 (2), 255-259, 1994 | 11 | 1994 |
| Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension LG Hegde, C Yu, C Madhavi, R Araki, J Villarreal, G Obedencio, A Kanta, ... BMC Pharmacology 11, 1-2, 2011 | 6 | 2011 |
| Wanted: Class VI Antiarrhythmic Drug Action; New Start for a Rational Drug Therapy HS Karagueuzian, U Klein Journal of heart health 5 (1), 2018 | 4 | 2018 |
| Proteinchemische Untersuchungen am Oxytocin-Rezeptor aus dem Myometrium U Klein | 2 | 1994 |
Mark von ZastrowProfessor of Psychiatry and Pharmacology, UCSFAdresse e-mail validée de ucsf.edu